

Heterozygote frequencies of common polymorphic markers of factor VIII (F8) and factor IX (F9) genes in indigenous Nepali population

Kanjaksha Ghosh¹, Pooja Kanani¹, Bishesh Sharma Poudyal², Shrimati Shetty¹, Sanu Maiya Kapali²

1. National Institute of Immunohaematology (ICMR), 13th Floor, KEM Hospital, Parel, Mumbai 400 012, India.
2. Nepal Haemophilia care Centre at National Academy of Medical Sciences Nepal.

OBJECTIVES

To determine heterozygote frequencies of common polymorphic markers of factor VIII (F8) and factor IX (F9) genes in indigenous Nepali population with an objective of application of the generated data for genetic diagnosis of affected families

Table 1. Heterozygote frequencies of the polymorphic markers of *f 8* and *f 9* genes in Nepali population

Marker	Allele frequency		Heterozygosity frequency
	+	-	
F8 gene			
Bcl1	0.63	0.37	0.38
Hind III	0.34	0.66	0.38
Bsl1	0.28	0.72	0.41
Bcl1 + Hind III	-	-	0.49
Bcl1+HindIII+Bsl1	-	-	0.54
F9 gene			
Dde1*	0.09	0.91	0.15
Hha1	0.19	0.81	0.41
Mse1	1.00	0	0
Hha1+Dde1	-	-	0.53
Hha1+Dde1+Mse1	-	-	0.53

METHODS

83 unrelated subjects (46 males and 37 females ; 120 X chromosomes) were included in the present study

Polymorphic markers studied:

Factor VIII gene -Bcl1, HindIII, Bsl1

Factor IX gene- Dde1, Hha1, Mse1

RESULTS

Cumulative heterozygotic frequency of Bcl1, Hind III and Bsl1 -54%

Mse1 polymorphism of F9 gene showed 0% heterozygotic frequency

Dde1 and Hha1 showed a cumulative heterozygosity of 53%.

CONCLUSIONS

- Nepali population shows considerable deviation from most of the other populations as far as the heterozygosity of some of the markers in *f8* and *f9* genes are concerned.
- Mse1 marker of *f9* gene may not be used in Nepali population.
- Other RFLP markers like VNTR at intron 7, intron 13 and intron 22 of *F8* gene need to be studied and Taq1, Xmn1, Sal1, Mnl1
- Using 3 polymorphic markers of *F8* and *F9* genes, more than half of the families can be offered genetic diagnosis in Nepal using the simple PCR-RFLP technique.

Acknowledgements

Authors are grateful to World Federation of Haemophilia (WFH) for providing IHTC fellowship to one of us (BSP). This study is a fruitful culmination of cooperative work between National Institute of Immunohaematology and Haemophilia centre at Nepal

REFERENCES

- Furer V, Samuels J. End-stage hemophilic arthropathy in a patient from a developing nation. *J Clin Rheumatol*. 2010 ;16:303.
- Rijal L, Neogi DS, Ansari MT, Khan SA, Yadav CS. Hemophilic pseudotumor--is there a role of radiotherapy? Literature review and a case report. *Nepal Med Coll J* 2010 ;12:193-7
- Shetty S, Ghosh K, Pathare A, Colah R, Badakare S, Mohanty D. Factor VIII and IX gene polymorphisms and carrier analysis in Indian population. *Am J Hematol* 1997 ;54:271-5.
- Peake IR, Lillicrap DP, Boulyjenkov V, Briet E, Chan V, Ginter EK, Kraus EM, Ljung R, Mannucci PM, Nicolaides K, et al. Haemophilia: strategies for carrier detection and prenatal diagnosis. *Bull World Health Organ* 1993;71:429-58
- Mukundan P, Shetty S, Kulkarni B, Ghosh K. Utility of an exon 14 BslI polymorphism for improved genetic diagnosis of hemophilia A in Indian population. *Prenat Diagn* 2008 ; 28 : 920-2.

